CureMatch Articles & News
New study in The Oncologist supports the use of blood-based tumor DNA (liquid biopsies) in hepatocellular carcinoma (HCC) to facilitate personalized medicine. The CureMatch decision support platform matches personalized drug combinations for liver cancer patients. SAN DIEGO, CA – March 26, 2018: A new cancer study[1] reports that next-generation sequencing of circulating tumor DNA (ctDNA) can provide therapeutically […]
CureMatch is honored to be selected to present at the 2018 Biocom Life Science Partnering Conference. The Conference is an exclusive global partnering and networking forum that brings together senior executives, bankers, venture capitalists, and business development professionals from leading pharmaceutical and biotech companies. CureMatch has developed a proprietary software platform aimed at guiding oncologists […]
CureMatch is proud to be one of the sponsors of this year’s 14th Moores Cancer Center Industry/Academia Translational Oncology Symposium which will be held on Thursday, February 22, 2018 (8am-6pm) at the Moores Cancer Center, located at 3855 Health Sciences Drive, La Jolla, CA 92093. Featuring Duane Roth Award Lecture Engineered T-Cells: The Sky’s the Limit Carl June, MD […]
CureMatch’s Tsigelny is a featured author in Briefings in Bioinformatics journal with a review on artificial intelligence’s usefulness in drug combination therapy recommendations. SAN DIEGO, CA – February 12, 2018: Igor F. Tsigelny, Ph.D., Co-founder and Chief Science Officer at CureMatch®, is the author of “Artificial intelligence in drug combination therapy” in Briefings in Bioinformatics […]
Molecular study offers insights for possible cure of treatment resistance and new drug possibilities based upon better understanding of the GRP78-Cripto Protein. CureMatch’s Tsigelny published in current Protein Science Journal article. SAN DIEGO, CA – January 31, 2018: Igor F. Tsigelny, Ph.D., Co-founder and Chief Science Officer at CureMatch®, is a senior author of “Cripto […]